SIR2446 / Sironax - LARVOL DELTA

A phase I randomized study to evaluate safety, pharmacokinetics, and pharmacodynamics of SIR2446M, a selective RIPK1 inhibitor, in healthy participants. (PubMed, Clin Transl Sci) - "SIR2446M had a rapid and sustained inhibitory effect on the activity of RIPK1, with an overall 90% target engagement at repeated doses ranging from 30 to 400 mg in peripheral blood mononuclear cells ex vivo stimulated to undergo necroptosis. The favorable safety, pharmacokinetic, and pharmacodynamic profile of SIR2446M in healthy participants supports its further clinical development in patients with degenerative and inflammatory diseases."

Clinical • Journal • P1 data • PK/PD data • Inflammation • Pain • RIPK1

A Study to Investigate the Safety of SIR2446M in Healthy Volunteers (ANZCTR) - P1 | N=114 | Completed | Sponsor: Sironax Aus Pty Ltd | Recruiting ➔ Completed

Trial completion • Inflammation